Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Membrane Single-pass type I membrane protein |
Domain |
PF07686 Immunoglobulin V-set domain |
Function |
- |
Biological Process |
GO:0001894 tissue homeostasis GO:0002064 epithelial cell development GO:0003382 epithelial cell morphogenesis GO:0007586 digestion GO:0010669 epithelial structure maintenance GO:0022600 digestive system process GO:0030277 maintenance of gastrointestinal epithelium GO:0048871 multicellular organismal homeostasis GO:0060249 anatomical structure homeostasis |
Molecular Function | - |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between VSIG1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of VSIG1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of VSIG1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of VSIG1 in various data sets.
|
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of VSIG1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of VSIG1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by VSIG1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of VSIG1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of VSIG1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between VSIG1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | VSIG1 |
Name | V-set and immunoglobulin domain containing 1 |
Aliases | MGC44287; 1700062D20Rik; GPA34; dJ889N15.1; glycoprotein A34; V-set and immunoglobulin domain-containing pro ...... |
Chromosomal Location | Xq22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting VSIG1 collected from DrugBank database. |
There is no record. |